Trademark Search  /  R2 REVLIMID/RITUXIMAB

R2 REVLIMID/RITUXIMAB

● Live · Registered

U.S. federal trademark · Serial No. 88655362 · Reg. No. 6073615

Mark
R2 REVLIMID/RITUXIMAB
Status
Registered
Serial Number
88655362
Registration No.
6073615
Filing Date
October 15, 2019
Registration Date
June 9, 2020
Class(es)
Class 005, Class 044

Owners

Celgene Corporation
03 · Summit, NJ, US
Celgene Corporation
03 · Summit, NJ, US
Celgene Corporation
03 · Summit, NJ, US

Goods & Services

Medical information and counseling in the field of pharmaceuticals and safety issues pertaining to pharmaceuticals, and providing medical information in the aforementioned fields by distributing written materials in connection therewith; programs in the nature of providing medical information and counseling in the field of lenalidomide and rituximab and safety issues pertaining to lenalidomide and rituximab, and providing medical information in the aforementioned fields by distributing written materials in connection therewith; providing a web site featuring medical information; providing an internet website for medical professionals and medical patients featuring medical information; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing pharmaceutical advice; providing medical information, consultancy and advisory services; all the aforementioned services relating to rituximab

Pharmaceutical preparations for the treatment of certain cancers; pharmaceutical preparations for the treatment of lymphoma; pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; all the aforementioned goods being comprised in part of rituximab

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "R2 REVLIMID/RITUXIMAB" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.